• Sanofi, Pfizer & Bristol Drugs Among the 12 Approvals to Look Out for in Q4

    12 days ago - By Xconomy

    The end of the year should see a flurry of new products reaching the market to break new commercial ground or shake up their respective therapeutic areas. Here, Scrip takes a look at 12 of the more interesting approvals expected in the coming months, with the help of analysts at Biomedtracker. Supernus Pharmaceuticals' SPN-812
    Indication : Attention Deficit Hyperactivity Disorder PDUFA Date : 8 November NDA - First Review Supernus Pharmaceuticals, Inc. should hear by 8 November whether the US Food and Drug Administration will approve SPN-812 , its novel non-stimulant treatment for the...
    Read more ...